সোমবার, ১১ ফেব্রুয়ারী, ২০১৩

CSHL scientists identify a new strategy for interfering with a potent cancer-causing gene

CSHL scientists identify a new strategy for interfering with a potent cancer-causing gene [ Back to EurekAlert! ] Public release date: 11-Feb-2013
[ | E-mail | Share Share ]

Contact: Edward Brydon
ebrydon@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory

The histone ubitquitin ligase protein RNF20 is required for MLL-rearranged leukemia amplification

Cold Spring Harbor, N.Y. Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics.

CSHL Assistant Professor Christopher Vakoc, M.D., Ph.D., and colleagues, including the group of Professor Robert Roeder Ph.D. at The Rockefeller University, report the characterization of a protein required for AML in a paper published today in the Proceedings of the National Academy of Sciences.

Screening of DNA packaging proteins calls attention to RNF20

About 5%-10% of AML is characterized by the rearrangement of a gene called MLL (Mixed-Lineage Leukemia). The MLL fusion proteins that result from this rearrangement are potent oncogenes -- cancer-causing genes. They are particularly common in infant acute leukemia, which is usually resistant to standard chemotherapy.

An emerging body of evidence implicates problems with chromatin, the packaging material for DNA within the cell nucleus, as a major cause of acute leukemia. Based on this, Vakoc's laboratory is searching for novel drug targets among chromatin proteins, with the hope of identifying new ways to fight this disease.

"We sifted through a class of proteins that add 'protein tags' to chromatin in a search for new therapeutic targets", says Eric Wang, a former technician in the Vakoc lab who led this study. Wang is currently a doctoral student at Johns Hopkins University. These 'protein tags' are called ubiquitin and constitute one of many ways to control which genes are switched 'ON' or 'OFF' in our cells.

The team identified a protein called RNF20 that attaches ubiquitin tags to chromatin as being essential for the formation of leukemias caused by MLL-rearrangements. When they suppressed the expression of RNF20, the researchers were able to decrease leukemia cell proliferation in living mice, extending their lifespan.

Upon closer examination, the team realized that by targeting RNF20 they prevent MLL-fusion proteins from being able to work. "When we reduce the levels of RNF20 in leukemia cells, they revert back to being more like normal blood cells", says Shinpei Kawaoka, a postdoc in the Vakoc lab who also was involved in the study.

Vakoc's team proposes a model in which leukemia cells of the MLL-rearranged subtype come to rely on RNF20 to maintain their gene expression program, implicating it as a potential therapeutic target. Small-molecule drugs that target other proteins involved in regulating ubiquitin tags already exist so it is possible that drugs targeting RNF20 could be developed in the future for the treatment of MLL-rearranged leukemia.

###

"Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia" is published online in the Proceedings of the National Academy of the USA on February 11, 2013. The authors are: Eric Wang, Shinpei Kawaoka, Ming Yu, Junwei Shi, Ting Ni, Wenjing Yang, Jun Zhu, Robert G. Roeder and Christopher R. Vakoc. The paper can be obtained online at doi: 10.1073/pnas.201301045

The research described in this release was supported by the following grants and funding agencies: A Starr Cancer Foundation Grant I4-A430 (to C.R.V. and R.G.R), the Edward P. Evans Foundation, Martin Sass Foundation, and F. M. Kirby Foundation for research support. C.R.V. is also supported by a Burroughs-Welcome Career Award for Medical

Scientists award and National Cancer Institute Cancer Center Support Grant Q:31 Development Funds (Grant CA45508)

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 360 scientists strong and its Meetings & Courses program hosts more than 12,500 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.

Written by: Edward Brydon, Science Writer | ebrydon@cshl.edu | 516-367-6822



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


CSHL scientists identify a new strategy for interfering with a potent cancer-causing gene [ Back to EurekAlert! ] Public release date: 11-Feb-2013
[ | E-mail | Share Share ]

Contact: Edward Brydon
ebrydon@cshl.edu
516-367-6822
Cold Spring Harbor Laboratory

The histone ubitquitin ligase protein RNF20 is required for MLL-rearranged leukemia amplification

Cold Spring Harbor, N.Y. Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics.

CSHL Assistant Professor Christopher Vakoc, M.D., Ph.D., and colleagues, including the group of Professor Robert Roeder Ph.D. at The Rockefeller University, report the characterization of a protein required for AML in a paper published today in the Proceedings of the National Academy of Sciences.

Screening of DNA packaging proteins calls attention to RNF20

About 5%-10% of AML is characterized by the rearrangement of a gene called MLL (Mixed-Lineage Leukemia). The MLL fusion proteins that result from this rearrangement are potent oncogenes -- cancer-causing genes. They are particularly common in infant acute leukemia, which is usually resistant to standard chemotherapy.

An emerging body of evidence implicates problems with chromatin, the packaging material for DNA within the cell nucleus, as a major cause of acute leukemia. Based on this, Vakoc's laboratory is searching for novel drug targets among chromatin proteins, with the hope of identifying new ways to fight this disease.

"We sifted through a class of proteins that add 'protein tags' to chromatin in a search for new therapeutic targets", says Eric Wang, a former technician in the Vakoc lab who led this study. Wang is currently a doctoral student at Johns Hopkins University. These 'protein tags' are called ubiquitin and constitute one of many ways to control which genes are switched 'ON' or 'OFF' in our cells.

The team identified a protein called RNF20 that attaches ubiquitin tags to chromatin as being essential for the formation of leukemias caused by MLL-rearrangements. When they suppressed the expression of RNF20, the researchers were able to decrease leukemia cell proliferation in living mice, extending their lifespan.

Upon closer examination, the team realized that by targeting RNF20 they prevent MLL-fusion proteins from being able to work. "When we reduce the levels of RNF20 in leukemia cells, they revert back to being more like normal blood cells", says Shinpei Kawaoka, a postdoc in the Vakoc lab who also was involved in the study.

Vakoc's team proposes a model in which leukemia cells of the MLL-rearranged subtype come to rely on RNF20 to maintain their gene expression program, implicating it as a potential therapeutic target. Small-molecule drugs that target other proteins involved in regulating ubiquitin tags already exist so it is possible that drugs targeting RNF20 could be developed in the future for the treatment of MLL-rearranged leukemia.

###

"Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia" is published online in the Proceedings of the National Academy of the USA on February 11, 2013. The authors are: Eric Wang, Shinpei Kawaoka, Ming Yu, Junwei Shi, Ting Ni, Wenjing Yang, Jun Zhu, Robert G. Roeder and Christopher R. Vakoc. The paper can be obtained online at doi: 10.1073/pnas.201301045

The research described in this release was supported by the following grants and funding agencies: A Starr Cancer Foundation Grant I4-A430 (to C.R.V. and R.G.R), the Edward P. Evans Foundation, Martin Sass Foundation, and F. M. Kirby Foundation for research support. C.R.V. is also supported by a Burroughs-Welcome Career Award for Medical

Scientists award and National Cancer Institute Cancer Center Support Grant Q:31 Development Funds (Grant CA45508)

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 360 scientists strong and its Meetings & Courses program hosts more than 12,500 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.

Written by: Edward Brydon, Science Writer | ebrydon@cshl.edu | 516-367-6822



[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-02/cshl-csi021113.php

north korea threat brandon jacobs brandon jacobs brian dawkins emma roberts north korea news north korea news

কোন মন্তব্য নেই:

একটি মন্তব্য পোস্ট করুন